- Home
- FOR vs COLL Comparison
FOR vs COLL Comparison
Compare FOR & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOR
- COLL
- Stock Information
- Founded
- FOR 2005
- COLL 2002
- Country
- FOR United States
- COLL United States
- Employees
- FOR N/A
- COLL N/A
- Industry
- FOR Real Estate
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- FOR Finance
- COLL Health Care
- Exchange
- FOR Nasdaq
- COLL Nasdaq
- Market Cap
- FOR 1.3B
- COLL 1.1B
- IPO Year
- FOR 2007
- COLL 2015
- Fundamental
- Price
- FOR $26.01
- COLL $36.00
- Analyst Decision
- FOR Strong Buy
- COLL Strong Buy
- Analyst Count
- FOR 4
- COLL 4
- Target Price
- FOR $32.50
- COLL $44.25
- AVG Volume (30 Days)
- FOR 127.9K
- COLL 325.7K
- Earning Date
- FOR 10-28-2025
- COLL 11-06-2025
- Dividend Yield
- FOR N/A
- COLL N/A
- EPS Growth
- FOR N/A
- COLL N/A
- EPS
- FOR 3.29
- COLL 1.06
- Revenue
- FOR $1,662,400,000.00
- COLL $707,007,000.00
- Revenue This Year
- FOR $1.60
- COLL $21.29
- Revenue Next Year
- FOR $16.64
- COLL $3.36
- P/E Ratio
- FOR $7.91
- COLL $34.00
- Revenue Growth
- FOR 10.14
- COLL 22.61
- 52 Week Low
- FOR $18.00
- COLL $23.23
- 52 Week High
- FOR $33.06
- COLL $39.95
- Technical
- Relative Strength Index (RSI)
- FOR 47.55
- COLL 58.95
- Support Level
- FOR $25.00
- COLL $33.89
- Resistance Level
- FOR $29.44
- COLL $35.90
- Average True Range (ATR)
- FOR 1.08
- COLL 1.02
- MACD
- FOR 0.08
- COLL 0.27
- Stochastic Oscillator
- FOR 32.28
- COLL 97.57
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.